Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP925386.RAQrYI3nBHyn8Fs4vnjgjrUiBsAmAvlSKX-i56i_HgSXM130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP925386.RAQrYI3nBHyn8Fs4vnjgjrUiBsAmAvlSKX-i56i_HgSXM130_assertion type Assertion NP925386.RAQrYI3nBHyn8Fs4vnjgjrUiBsAmAvlSKX-i56i_HgSXM130_head.
- NP925386.RAQrYI3nBHyn8Fs4vnjgjrUiBsAmAvlSKX-i56i_HgSXM130_assertion wasGeneratedBy ECO_0000203 NP925386.RAQrYI3nBHyn8Fs4vnjgjrUiBsAmAvlSKX-i56i_HgSXM130_provenance.
- NP925386.RAQrYI3nBHyn8Fs4vnjgjrUiBsAmAvlSKX-i56i_HgSXM130_assertion wasDerivedFrom befree-20150227 NP925386.RAQrYI3nBHyn8Fs4vnjgjrUiBsAmAvlSKX-i56i_HgSXM130_provenance.
- NP925386.RAQrYI3nBHyn8Fs4vnjgjrUiBsAmAvlSKX-i56i_HgSXM130_assertion SIO_000772 17688376 NP925386.RAQrYI3nBHyn8Fs4vnjgjrUiBsAmAvlSKX-i56i_HgSXM130_provenance.
- NP925386.RAQrYI3nBHyn8Fs4vnjgjrUiBsAmAvlSKX-i56i_HgSXM130_assertion evidence source_evidence_literature NP925386.RAQrYI3nBHyn8Fs4vnjgjrUiBsAmAvlSKX-i56i_HgSXM130_provenance.
- NP925386.RAQrYI3nBHyn8Fs4vnjgjrUiBsAmAvlSKX-i56i_HgSXM130_assertion description "[55 patients with locally advanced rectal carcinoma (cT3-4, N0, M0 or cT2-4,N+, M0) were treated with capecitabine 825 mg/m2 twice a day and pelvic radiotherapy 1,8 Gy daily up to cumulative dose of 45 Gy, boosting up to 50,4 Gy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP925386.RAQrYI3nBHyn8Fs4vnjgjrUiBsAmAvlSKX-i56i_HgSXM130_provenance.